

Title: A systematic review of the uptake and adherence rates to supervised exercise programmes in patients with intermittent claudication.

Authors:

Harwood AE, Smith GE, Cayton T, Broadbent E & Chetter IC

Institution:

Academic Vascular Surgical Unit, Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ

Corresponding author:

Miss Amy-Elizabeth Harwood
PhD research in “Vascular disease and exercise mechanisms”

Academic Vascular Surgical Unit
Hull Royal Infirmary
Anlaby Road
HU3 2JZ

Email: Amy.Harwood@hey.nhs.uk

Funding: Miss Harwood is funded by a University of Hull PhD scholarship

Category: Review

Previously not published / presented

©2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International <http://creativecommons.org/licenses/by-nc-nd/4.0/>

Introduction: Intermittent claudication (IC) is a common and debilitating symptom of peripheral arterial disease and is associated with a significant reduction in a sufferer's quality of life. Guidelines recommend a supervised exercise programme (SEP) as the primary treatment option; however, anecdotally there is a low participation rate for exercise in this group of patients. We undertook a systematic review of the uptake and adherence rates to supervised exercise programmes for individuals with IC.

Methods: The Medline, Embase and PubMed databases were searched up to January 2015 for terms related to supervised exercise in peripheral arterial disease. The review had three aims: firstly to establish the rates of uptake to SEPs, secondly the rates of adherence to programmes and finally to determine the reasons reported for poor uptake and adherence. Separate inclusion/exclusion criteria were applied in selecting reports for each aim of the review.

Results: Only 23 of the 53 potentially eligible papers for uptake analysis identified on literature searches reported any details of screened patients (n = 7517) with only 24.2% of patients subsequently recruited to SEPs. Forty-five percent of screen failures had no reason for exclusion reported. 67 papers with 4012 patients were included for analysis of SEP adherence. Overall 75.1% of patients reportedly completed a SEP, however only one paper defined a minimal attendance required for SEP completion. 54.1% of incomplete adherence was due to patient withdrawal and no reason for incomplete adherence was reported for 16% of cases.

Discussion: Reporting of SEP trials was poor with regard the numbers of subjects screened and reasons for exclusions. Only approximately 1 in 3 screened IC patients was suitable for and willing to undertake SEP. Levels of adherence to SEPs and definitions of satisfactory adherence were also lacking in the majority of the current literature. Current clinical guidelines based upon this evidence base may not be applicable to the majority of IC patients and changes to SEPs may be needed to encourage/retain participants.

Introduction

Intermittent claudication (IC) is the most common symptom of peripheral arterial disease (PAD), affecting 5 % of the population over the age of 50 years ¹ and 20 % of the population over 70 years ². IC is due to muscle ischemia precipitated by exercise and is frequently associated with a reduction in walking capabilities ³. Supervised exercise programmes (SEPs) for patients with claudication have been demonstrated to improve walking distances and be cost effective ⁴. Current clinical guidelines recommend that all patients with IC are enrolled on a group-based SEP ^{5,6}. Furthermore, centres should consider a programme comprised of intermittent walking to near maximal or maximal pain, three times a week, for a minimum of 12 weeks ⁷.

Although it is agreed that supervised exercise should be the first line treatment, there is evidence suggesting that relatively few patients are suitable for and will agree to participation in an SEP⁸. Many who commence an SEP fail to complete the programme of classes. Clearly the clinical and cost effectiveness of SEPs for managing the population of IC patients as a whole may be significantly affected by poor recruitment and adherence to programmes.

This review has 3 aims, firstly to establish from the existing literature the levels of uptake of SEPs in published trials, which we defined as the proportion of screened patients who went on to commence an SEP. Secondly to determine patient adherence to SEPs, which was defined as the proportion of patients who commenced an SEP and subsequently completed all sessions. Thirdly to explore what reasons were reported for lack of uptake or adherence in IC patients.

Methods

A systematic review of randomised and non-randomised clinical trials (RCTs) including a SEP arm was performed. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for reporting of search results⁹.

Search Strategy

Systematic review was performed using Medline, Embase and CENTRAL. The search strategy aimed to include any trials which included SEP either as the control arm or as the primary intervention. Search terms used were:

‘peripheral arterial disease’ [OR] ‘intermittent claudication’ [OR] ‘claudication’ [OR] ‘ischemia’ [AND], ‘exercise’ [OR] ‘running’ [OR] ‘exercise therapy’ [OR] ‘exercise movement’ [OR] ‘training’ [AND] ‘supervised’.

Searches were limited to run from 1947 to January 2015. The search was limited to full text articles relating to adults (over 18 years of age) and published in English. Abstracts identified by the database search were independently interrogated for relevance by two reviewers (AH & TC). Citations from the full texts of relevant reports were hand searched for other relevant references.

Inclusion criteria

Two cohorts of reports were selected from within the search results, firstly to assess data on rates of uptake, then data on rates of adherence to SEPs. Both cohorts were then examined for reporting of reasons for poor uptake and adherence. For both searches, we included randomised and prospective non-randomised studies that investigated the role of SEPs in patients diagnosed with Intermittent Claudication (Fontaine II/ Rutherford 1-3). These were either diagnosed clinically or by interview/ questionnaire. We included any form of SEP regardless of the structure, duration, frequency or intensity of training utilised. Papers were only included if they specifically reported the numbers of subjects recruited to, commencing and completing the SEP. Any studies including patients who were asymptomatic were excluded.

Rate of SEP Uptake cohort:

In an attempt to avoid bias, studies were excluded from this cohort if they included any active interventions other than an SEP (e.g. medications/supplements, angioplasty, surgery). The rationale for exclusion was so that patients refusing to participate would not have been deterred by the possibility of randomisation to any treatment other than the SEP. Data was collected to include numbers screened and numbers of patients who were subsequently allocated to an SEP and attended at least one session.

Adherence to SEPs cohort:

All Studies involving an SEP arm versus any other comparator arm were included in this cohort. Data extraction was then limited to the subjects assigned to the SEP arm(s) with regard to rates of SEP adherence.

Data extraction

Any disagreement as to inclusion of a report between the two assessing investigators (AH,TC) was settled by consensus with a third (GS). Data extraction was then performed by two investigators (AH, TC) using a standardised data extraction sheet. Data regarding research unit and country, target population, numbers of patients initially screened/referred for SEP, number of participants enrolled to SEP, reasons for non-enrolment, number of dropouts prior to completion of SEP, reasons for dropout and description of the supervised exercise protocol, (frequency, duration, content) were collected.

Results

Search results

The search yielded a total of 333 reports of which 11 were duplicates. Of the remaining 322, 67 were appropriate for inclusion in one or both sections of the planned analysis. The inclusion/exclusion process is summarised in figure 1.

Included trials

Our analysis included 67 trials, all of which utilised some form of SEP in claudicants and recorded details of recruited subjects and numbers of those who commenced and completed an SEP. 52 reports were from randomised trials and the remainder were prospective case control or cohort studies. The total of recruited subjects within the 67 papers was 5817, with 4094 subjects assigned to a study arm which included a SEP. SEPs differed widely between reports both in duration (varying from 4 weeks to 12 months) and in type of exercise undertaken (resistance, aerobic, combination - upper/ lower limb). Included studies are summarised in Table 1.

<u>Author</u>	<u>Year</u>	<u>Total Recruited</u>	<u>Assigned SEP</u>	<u>% Uptake</u>	<u>% Adherence</u>	<u>SEP Duration</u>	<u>X Per week</u>	<u>Type</u>
---------------	-------------	------------------------	---------------------	-----------------	--------------------	---------------------	-------------------	-------------

						(Weeks)		
Allen ¹⁰	2014	27	27	100	100	12	3	Aerobic
Andreozzi ¹¹	2008	44	44	100	100	6	3	Walking
Beckitt ¹²	2012	38	27	100	100	12	3	Mixed
Beckitt ¹²	2012	56	42	100	100	12	3	Mixed
Bendermacher ⁶	2007	39	39	100	60	52	3	Mixed
Bo ¹³	2013	50	29	100	100	12	3	Walking
Bronas ¹⁴	2011	40	20	100	100	12	3	Mixed
Cheetham ¹⁵	2004	59	29	100	100	12	1	Mixed
CLEVER ¹⁶	2012	119	51	96	92	26	3	Walking
Collins ¹⁷	2005	52	27	100	85	24	3	Walking
Collins ¹⁸	2012	146	103	100	94	24	3	Walking
Crowther ¹⁹	2009	21	10	100	100	52	3	Walking
Degischer ²⁰	2002	69	38	100	100	12	3	Walking
Delaney ²¹	2014	35	35	100	77	12	3	Mixed
Duscha ²²	2011	78	78	100	35	12	3	Walking
Fokkenrood ²³	2015	47	47	100	87	12	3	Mixed
Frans	2010	101	101	100	71	12	3	Walking
Gardner ²⁴	2012	142	106	100	76	104	3	Walking
Gardner ²⁵	2014	180	60	100	87	12	3	Walking
Gardner ²⁶	2005	77	77	100	83	24	3	Walking
Gardner ²⁷	2001	61	31	90	100	24	3	Walking
Gelin ²⁸	2001	264	73	100	59	24	3	Walking
Greenhalgh ²⁹	2008	144	60	100	82	24	1	Mixed
Hiatt ³⁰	1990	25	14	100	71	12	3	Walking
Hiatt ³¹	1994	29	19	100	100	12	3	Walking OR Resistance
Hiatt ³²	2011	69	69	100	86	24	3	Walking
Hobbs ³³	2007	38	19	84	100	12	2	Walking
Hodges ³⁴	2008	28	14	50	100	12	2	Walking
Janusek ³⁵	2014	85	85	100	79	12	3	Walking
Jones ³⁶	2012	22	12	100	100	12	3	Walking
Jones ³⁷	1996	23	23	100	52	12	2	Walking
Kakkos ³⁸	2005	36	12	100	50	24	3	Walking
King ³⁹	2012	12	12	100	92	12	3	Mixed
Kruideiner ⁴⁰	2011	70	35	100	77	52	3	Mixed
Kruideiner ⁴¹	2009	349	297	92	47	52	3	Mixed
Leicht ⁴²	2011	25	12	100	67	52	3	Walking
Mazari ⁴³	2012	178	118	85	93	12	3	Mixed
Meneses ⁴⁴	2011	34	34	100	88	52	2	Mixed
Mika ⁴⁵	2005	98	49	100	16	12	3	Walking
Mika ⁴⁶	2006	60	30	100	90	12	3	Walking
Mika ⁴⁷	2011	68	34	100	88	12	3	Walking

Mockford ⁴⁸	2014	51	51	100	96	12	3	Mixed
Nicolai ⁴⁹	2010	304	202	99	45	12	3	Walking
Parmenter ⁵⁰	2013	22	15	100	93	24	3	Resistance
Regensteiner ⁵¹	1996	29	19	100	79	12	3	Mixed
Sakamoto ⁵²	2009	118	118	100	54	52	3	Walking
Savage ⁵³	2001	21	21	52	100	12	3	Walking
Schlager ⁵⁴	2011	40	20	100	100	24	2	Walking
Slordahl ⁵⁵	2005	16	16	100	100	8	3	Aerobic
Spronk ⁵⁶	2010	151	75	100	96	24	2	Walking
Stewart ⁵⁷	2008	60	30	100	91	24	2	Mixed
Tew ⁵⁸	2009	57	29	100	93	12	2	aerobic
Treat-Jacobson ⁵⁹	2009	62	37	100	78	12	3	Walking
Tsai ⁶⁰	2002	64	32	100	85	12	3	Walking
Van Pul ⁶¹	2012	775	775	100	59	24	3	Walking
Versluis ⁶²	2013	10	10	100	100	12	2 / 3	Walking
Walker ⁶³	2000	52	52	100	92	6	2	Mixed
Wang ⁶⁴	2007	22	17	77	100	12	3	Walking
Wang ⁶⁵	2008	27	14	100	100	12	3	Walking
Wang ⁶⁶	2010	10	10	100	100	8	3	Strength
Zweirska ⁶⁷	2005	104	71	100	87	24	2	Aerobic

Uptake of supervised exercise

53 studies met the inclusion criteria for the uptake of an exercise protocol section of the review. However, only 23 of the 53 papers gave any details of total numbers of potential participants screened for participation. Within these reports 1820 subjects recruited from 7517 screened (24.2%).

Analysis of recruited patients from all 53 studies, showed 3296 were assigned to study arms which included a SEP as an intervention. There was a 98.1% rate of subjects assigned to SEP arms commencing SEP intervention following randomisation (3235 of 3296 subjects).

Supervised Exercise adherence

An additional 14 papers met the criteria for inclusion in the adherence to exercise programmes section of the review. These reports included comparator interventions of arterial surgery, angioplasty and medical therapies either alone or as adjuvants to SEP. A total of 67 papers were included in this analysis with a total of 5817 recruited subjects.

Any patient assigned to any arm which required SEP was included in the assessment of adherence to programmes. Of the 4012 subjects who commenced an SEP in the included trials, 3015 were reported as having adequately completed the exercise programme for inclusion in the analysis (75.1%). No paper gave a clear definition of the number of sessions attended that was considered the minimum for a subject to have completed the SEP intervention.

Eight reports included specific comments regarding levels of adherence with the programmes. Descriptions of adherence were as overall percentage attendance at sessions in 3 papers^{63, 68, 69} percentage of subjects attending at least a certain proportion of total sessions in 3 papers^{14, 32, 59} and two papers reported both^{60, 69}.

Reasons for screen failure and poor uptake or adherence

Screen failures:

The level of detail in reporting reasons for screen failures was highly variable, with two papers accounting for every patient^{57, 70}, whilst several others reported only “screen failure” in accounting for patients who were not recruited.

Of the 23 reports specifying total numbers of patients screened, with a cumulative total of 7517 screened for 1820 patients recruited, there were 5697 screen failures. Of these screen failures, 2566 (45%) did not have a reason for screen failure specified (reported only as “screen failure” or “other”). A further 614 patients had a list of reasons for exclusions reported but without quantifying the number of patients excluded for each reason. Thus only 2517 screen failures had quantified reasons for non-inclusion and these are shown grouped into categories and ranked by frequency in table 2.

10 papers reported uptake of less than 100% with 89 randomised patients failing to commence SEP. Five reports (33 patients) stated only “did not receive intervention” or gave no reasons for incomplete uptake. Where reasons were reported, patient withdrawal was the most frequent and insurance, exacerbation of co-morbidities or death also reported.

Poor adherence:

Again, reports varied widely in level of detail provided as to reasons for incomplete adherence to SEPS. Forty five of the 67 papers with a total of 3518 SEP patients reported incomplete adherence amongst 1066 study patients (30.3%). Of these 171 patients (16%) did not have a reason for incomplete adherence specified (no reasons given in report or “other specified”). A further 71 patients had a list of reasons for incomplete adherence reported but without quantifying the number of patients associated with each reason. Thus only 824 patients had quantified reasons for incomplete adherence and these are shown grouped into categories and ranked by frequency in table three.

1 **Discussion**

2 SEPs have been shown to be both clinically and cost effective in treatment of IC and there is
3 a wealth of evidence supporting the recommendation of SEP as the first line treatment for
4 IC. However the results of this review suggest that this evidence may not be universally
5 applicable to the IC population as a whole.

6 The majority of trials included in this review gave no indication of numbers of IC patients
7 screened for inclusion which makes the application of their results difficult. Where
8 screening information was reported many of the reasons for non-inclusion are not recorded.
9 For those with reasons for exclusion, almost 1 in 3 were excluded due to refusal on the part
10 of the patient (30.6 %).Co-morbidities preventing exercise followed (16.2 %) with inability to
11 attend classes due to location or timing (11.7 %) preventing a further 1 in 4 from
12 participating. Clearly the results presented here may include some level of negative bias as
13 participants were being screened / assessed for inclusion in both a clinical trial as well as an
14 SEP, potentially reducing the numbers of eligible or amenable recruits. However,
15 approximately only 1 in every 3 of the screened IC patient population is eligible and willing
16 to be included in an SEP as part of the included trials. This finding is very similar to results
17 reported by Muller-Buhl in a prospective observational study who found that only 36% of
18 their referrals to a SEP for IC were suitable for participation⁸. Thus the patients studied in
19 the majority of the included trials, which represent the bulk of the available evidence upon
20 which current recommendations are based, may therefore represent a better motivated
21 and less co-morbid cohort within the overall population of IC patients.

22
23 For subjects who were willing and able to participate the rate of uptake once allocated to a
24 SEP as part of a trial was excellent (98.1%).This may however be an effect of selection bias in
25 that this group has agreed to participate in SEP in a trial and is likely a subsection of
26 claudicants with a high level of motivation or willingness to change. Data from our own SEP
27 (personal communication) and those of Muller-Buhl suggest that as few as 24% of eligible
28 patients will actually attend SEP sessions despite initially agreeing to participate when
29 referred.

30

31 Overall adherence was reported as 75% for those subjects allocated to SEP though very few
32 reports gave any specific figures for adherence within their study populations. Furthermore
33 only one defined a target figure for attendance that determined acceptable attendance. It is
34 very possible that the specifics of the SEP might influence the rate of uptake and adherence.
35 There was a very wide range of SEPS included in this review (table 1) including aerobic and
36 resistance training with varied frequencies over markedly different durations. It is also
37 interesting to note that those trials with the lowest levels of uptake and adherence tended
38 to be those with longer duration, frequency and reduced variety in the activity performed.

39
40

41 Patient lack of motivation was a major reason for screen failure and for poor adherence as
42 shown in Table 2 and 3. Improving this willingness to exercise relies on an understanding of
43 why patients refuse to undertake SEP, which is not available in the included reports.
44 However vascular patients are often a group who have made certain unhealthy lifestyle
45 choices and whom are perhaps amongst the least likely patients to embrace an ongoing
46 commitment to taking responsibility for their own health⁷¹. A further point to note is that
47 current recommendations^{7,72} promote walking to the point of claudication and beyond This
48 pain may discourage some patients from participating. A review by Parmenter et al⁷³ has
49 provided evidence to suggest that clinically relevant improvements in walking distance can
50 be attained at a lower threshold and without inducing pain. A further review by Al-Jundi et
51 al⁷⁴ also highlights this point concluding that avoidance of painful exercise may lead to
52 higher participation rates and make it more likely for patients to maintain behavioural
53 changes in the longer term.

54

55 Co-morbidities were the reason a significant proportion of patients were not enrolled in or
56 failed to complete SEPs in this review. To highlight this further, death was the third most
57 frequent reason reported for incomplete adherence to SEP. Some of these patients are
58 simply unable to exercise to any extent due to arthritis, angina or breathlessness rendering
59 them entirely unsuitable for SEP. Others may not be referred due to the perception that
60 systemic cardiovascular disease may make it unsafe for IC patients to undertake exercise.
61 This was challenged in a systematic review of SEP safety which noted an all-cause

62 complication rate of one event per 10,340 patient-hours of SEP ⁷⁵. However this review was
63 based upon published trials of SEP (similar to those included in this review, many of which
64 will have already excluded the more co-morbid patients) and so again may not reflect the
65 risk for the IC population as a whole.

66

67 Other reasons given for non-inclusion or poor adherence were mainly logistical (travel,
68 work/family commitment). It may be argued that a way of improving the participation rate
69 for IC patients would be to promote unsupervised exercise; the old “go home and walk” ⁷⁶
70 adage but comparisons of supervised versus unsupervised exercise clearly demonstrates
71 that this is not an effective treatment strategy. It also has worse adherence rates in
72 comparison to supervised programmes ⁶. To counter this there has been a greater interest
73 in the “home-exercise” programme (HEP) which is potentially more convenient for patients
74 particularly within the working demographic range. A systematic review ⁷⁴ has provided
75 some evidence that HEP can demonstrate improvements in walking distances and quality of
76 life in patients with IC. Though the authors conclude that this improvement was still not
77 equivalent to that achieved by an SEP and, in common with the findings of this review, the
78 studies included did not clearly present exercise adherence or decline rates ⁷⁴. Additionally,
79 the use of personal health-devices such as pedometers or smart phone apps has also had
80 some beneficial effects in the IC population ²⁵. These can be used in conjunction with a
81 home-exercise programme to help the clinician monitor the patient’s compliance to the
82 exercise training. They may also have a motivational effect via visual and quantitative
83 feedback.

84

85 It remains to be established exactly what might constitute the “ideal” exercise training
86 programme and indeed there may well be different ideal programmes for clinical
87 effectiveness and for patient satisfaction, uptake and adherence. Evidence of efficacy for
88 the patients who have undertaken SEP is compelling and improving the uptake of SEP for
89 those able to exercise is a significant challenge. Examining the reasons for poor uptake and
90 or adherence may allow SEP providers with insight as to how to increase participation in
91 SEP.

92

93 **Conclusions**

94 Details of populations screened, reasons for exclusion and definitions of adequate uptake
95 and adherence were lacking in the majority of reports. Where data was reported, only 1 in
96 3 patients screened were suitable for and willing to undertake SEP. This has potential
97 implications for the recommendation of SEP as first line treatment for *all* IC patients as
98 there may be a significant proportion of patients where SEP treatment is not accepted or
99 possible. Future reports regarding SEP trials need to include full details of screened
100 populations, and rates of uptake and adherence to exercise. This will ensure more
101 consistent reporting of data and allow for findings to be interpreted with greater clarity.

102

103 Ultimately the prescription of SEP in the IC population is effective and beneficial but the
104 results from this review suggest that it is not a “one-size fits all” model. Future research into
105 the development of more accessible and or acceptable SEPS may improve current uptake
106 and adherence rates.

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122 **References**

123

- 124 1. Szuba A, Oka RK, Harada R, Cooke JP. Limb hemodynamics are not predictive of functional
125 capacity in patients with PAD. *Vasc Med.* 2006;11(3):155-63.
- 126 2. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the
127 United States: results from the National Health and Nutrition Examination Survey, 1999-2000.
128 *Circulation.* 2004;110(6):738-43.
- 129 3. Beebe HG. Intermittent claudication: effective medical management of a common
130 circulatory problem. *The American journal of cardiology.* 2001;87(12A):14D-8D.
- 131 4. Lee HL, Mehta T, Ray B, Heng MS, McCollum PT, Chetter IC. A non-randomised controlled
132 trial of the clinical and cost effectiveness of a Supervised Exercise Programme for claudication.
133 *European journal of vascular and endovascular surgery : the official journal of the European Society
134 for Vascular Surgery.* 2007;33(2):202-7.
- 135 5. Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. *Cochrane Database Syst
136 Rev.* 2008(4):Cd000990.
- 137 6. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus
138 non-supervised exercise therapy for intermittent claudication. *The Cochrane database of systematic
139 reviews.* 2006(2):CD005263.
- 140 7. Hirsch AT, Haskal ZJ, Hertzner NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA
141 Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal,
142 mesenteric, and abdominal aortic): a collaborative report from the American Associations for
143 Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and
144 Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and
145 the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the
146 management of patients with peripheral arterial disease)--summary of recommendations. *Journal of
147 vascular and interventional radiology : JVIR.* 2006;17(9):1383-97; quiz 98.
- 148 8. Muller-Buhl U, Engeser P, Leutgeb R, Szecsenyi J. Low attendance of patients with
149 intermittent claudication in a German community-based walking exercise program. *International
150 angiology : a journal of the International Union of Angiology.* 2012;31(3):271-5.
- 151 9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA
152 statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare
153 interventions: explanation and elaboration. *Bmj.* 2009;339:b2700.
- 154 10. Allen JD, Stabler T, Kenjale AA, Ham KL, Robbins JL, Duscha BD, et al. Diabetes status
155 differentiates endothelial function and plasma nitrite response to exercise stress in peripheral
156 arterial disease following supervised training. *Journal of diabetes and its complications.*
157 2014;28(2):219-25.
- 158 11. Andreozzi GM, Leone A, Laudani R, Martin R, Deinit G, Cataldi V. Levo-propionyl-carnitine
159 improves the effectiveness of supervised physical training on the absolute claudication distance in
160 patients with intermittent claudication. *Angiology.* 2008;59(1):84-9.
- 161 12. Beckitt TA, Day J, Morgan M, Lamont PM. Calf muscle oxygen saturation and the effects of
162 supervised exercise training for intermittent claudication. *Journal of vascular surgery.*
163 2012;56(2):470-5.
- 164 13. Bo E, Hisdal J, Cvancarova M, Strandén E, Jorgensen JJ, Sandbaek G, et al. Twelve-months
165 follow-up of supervised exercise after percutaneous transluminal angioplasty for intermittent
166 claudication: a randomised clinical trial. *International journal of environmental research and public
167 health.* 2013;10(11):5998-6014.

- 168 14. Bronas UG, Hirsch AT, Murphy T, Badenhop D, Collins TC, Ehrman JK, et al. Design of the
169 multicenter standardized supervised exercise training intervention for the claudication: exercise vs
170 endoluminal revascularization (CLEVER) study. *Vasc Med*. 2009;14(4):313-21.
- 171 15. Cheetham DR, Burgess L, Ellis M, Williams A, Greenhalgh RM, Davies AH. Does supervised
172 exercise offer adjuvant benefit over exercise advice alone for the treatment of intermittent
173 claudication? A randomised trial. *European journal of vascular and endovascular surgery : the official
174 journal of the European Society for Vascular Surgery*. 2004;27(1):17-23.
- 175 16. Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, 3rd, Cohen DJ, Reynolds MR, et al.
176 Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac
177 peripheral artery disease: the CLEVER study. *Journal of the American College of Cardiology*.
178 2015;65(10):999-1009.
- 179 17. Collins TC, Petersen NJ, Suarez-Almazor M. Peripheral arterial disease symptom subtype and
180 walking impairment. *Vasc Med*. 2005;10(3):177-83.
- 181 18. Collins EG, O'Connell S, McBurney C, Jelinek C, Butler J, Reda D, et al. Comparison of walking
182 with poles and traditional walking for peripheral arterial disease rehabilitation. *Journal of
183 cardiopulmonary rehabilitation and prevention*. 2012;32(4):210-8.
- 184 19. Crowther RG, Spinks WL, Leicht AS, Sangla K, Quigley F, Golledge J. The influence of a long
185 term exercise program on lower limb movement variability and walking performance in patients
186 with peripheral arterial disease. *Human movement science*. 2009;28(4):494-503.
- 187 20. Degischer S, Labs KH, Hochstrasser J, Aschwanden M, Tschoepf M, Jaeger KA. Physical
188 training for intermittent claudication: a comparison of structured rehabilitation versus home-based
189 training. *Vasc Med*. 2002;7(2):109-15.
- 190 21. Delaney CL, Miller MD, Chataway TK, Spark JI. A randomised controlled trial of supervised
191 exercise regimens and their impact on walking performance, skeletal muscle mass and calpain
192 activity in patients with intermittent claudication. *European journal of vascular and endovascular
193 surgery : the official journal of the European Society for Vascular Surgery*. 2014;47(3):304-10.
- 194 22. Duscha BD, Robbins JL, Jones WS, Kraus WE, Lye RJ, Sanders JM, et al. Angiogenesis in
195 skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients.
196 *Arteriosclerosis, thrombosis, and vascular biology*. 2011;31(11):2742-8.
- 197 23. Fokkenrood HJ, Lauret GJ, Verhofstad N, Bendermacher BL, Scheltinga MR, Teijink JA. The
198 effect of supervised exercise therapy on physical activity and ambulatory activities in patients with
199 intermittent claudication. *European journal of vascular and endovascular surgery : the official
200 journal of the European Society for Vascular Surgery*. 2015;49(2):184-91.
- 201 24. Gardner AW, Montgomery PS, Parker DE. Optimal exercise program length for patients with
202 claudication. *Journal of vascular surgery*. 2012;55(5):1346-54.
- 203 25. Gardner AW, Parker DE, Montgomery PS, Blevins SM. Step-monitored home exercise
204 improves ambulation, vascular function, and inflammation in symptomatic patients with peripheral
205 artery disease: a randomized controlled trial. *Journal of the American Heart Association*.
206 2014;3(5):e001107.
- 207 26. Gardner AW, Montgomery PS, Flinn WR, Katzel LI. The effect of exercise intensity on the
208 response to exercise rehabilitation in patients with intermittent claudication. *Journal of vascular
209 surgery*. 2005;42(4):702-9.
- 210 27. Gardner AW, Katzel LI, Sorkin JD, Bradham DD, Hochberg MC, Flinn WR, et al. Exercise
211 rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent
212 claudication: a randomized controlled trial. *Journal of the American Geriatrics Society*.
213 2001;49(6):755-62.
- 214 28. Gelin J, Jivegard L, Taft C, Karlsson J, Sullivan M, Dahllof AG, et al. Treatment efficacy of
215 intermittent claudication by surgical intervention, supervised physical exercise training compared to
216 no treatment in unselected randomised patients I: one year results of functional and physiological

217 improvements. *European journal of vascular and endovascular surgery : the official journal of the*
218 *European Society for Vascular Surgery.* 2001;22(2):107-13.

219 29. Greenhalgh RM, Belch JJ, Brown LC, Gaines PA, Gao L, Reise JA, et al. The adjuvant benefit of
220 angioplasty in patients with mild to moderate intermittent claudication (MIMIC) managed by
221 supervised exercise, smoking cessation advice and best medical therapy: results from two
222 randomised trials for stenotic femoropopliteal and aortoiliac arterial disease. *European journal of*
223 *vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.*
224 2008;36(6):680-8.

225 30. Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP. Benefit of exercise
226 conditioning for patients with peripheral arterial disease. *Circulation.* 1990;81(2):602-9.

227 31. Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of treadmill walking exercise
228 versus strength training for patients with peripheral arterial disease. Implications for the mechanism
229 of the training response. *Circulation.* 1994;90(4):1866-74.

230 32. Hiatt WR, Creager MA, Amato A, Brass EP. Effect of propionyl-L-carnitine on a background of
231 monitored exercise in patients with claudication secondary to peripheral artery disease. *Journal of*
232 *cardiopulmonary rehabilitation and prevention.* 2011;31(2):125-32.

233 33. Hobbs SD, Marshall T, Fegan C, Adam DJ, Bradbury AW. The effect of supervised exercise
234 and cilostazol on coagulation and fibrinolysis in intermittent claudication: a randomized controlled
235 trial. *Journal of vascular surgery.* 2007;45(1):65-70; discussion

236 34. Hodges LD, Sandercock GR, Das SK, Brodie DA. Randomized controlled trial of supervised
237 exercise to evaluate changes in cardiac function in patients with peripheral atherosclerotic disease.
238 *Clinical physiology and functional imaging.* 2008;28(1):32-7.

239 35. Januszek R, Mika P, Konik A, Petriczek T, Nowobilski R, Nizankowski R. The effect of treadmill
240 training on endothelial function and walking abilities in patients with peripheral arterial disease.
241 *Journal of cardiology.* 2014;64(2):145-51.

242 36. Jones WS, Duscha BD, Robbins JL, Duggan NN, Regensteiner JG, Kraus WE, et al. Alteration in
243 angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of
244 patients with intermittent claudication following exercise training. *Vasc Med.* 2012;17(2):94-100.

245 37. Jones PP, Skinner JS, Smith LK, John FM, Bryant CX. Functional improvements following
246 StairMaster vs. treadmill exercise training for patients with intermittent claudication. *Journal of*
247 *cardiopulmonary rehabilitation.* 1996;16(1):47-55.

248 38. Kakkos SK, Geroulakos G, Nicolaides AN. Improvement of the walking ability in intermittent
249 claudication due to superficial femoral artery occlusion with supervised exercise and pneumatic foot
250 and calf compression: a randomised controlled trial. *European journal of vascular and endovascular*
251 *surgery : the official journal of the European Society for Vascular Surgery.* 2005;30(2):164-75.

252 39. King S, Vanicek N, Mockford KA, Coughlin PA. The effect of a 3-month supervised exercise
253 programme on gait parameters of patients with peripheral arterial disease and intermittent
254 claudication. *Clinical biomechanics.* 2012;27(8):845-51.

255 40. Kruidenier LM, Nicolai SP, Rouwet EV, Peters RJ, Prins MH, Teijink JA. Additional supervised
256 exercise therapy after a percutaneous vascular intervention for peripheral arterial disease: a
257 randomized clinical trial. *Journal of vascular and interventional radiology : JVIR.* 2011;22(7):961-8.

258 41. Kruidenier LM, Nicolai SP, Hendriks EJ, Bollen EC, Prins MH, Teijink JA. Supervised exercise
259 therapy for intermittent claudication in daily practice. *Journal of vascular surgery.* 2009;49(2):363-
260 70.

261 42. Leicht AS, Crowther RG, Golledge J. Influence of peripheral arterial disease and supervised
262 walking on heart rate variability. *Journal of vascular surgery.* 2011;54(5):1352-9.

263 43. Mazari FA, Khan JA, Carradice D, Samuel N, Abdul Rahman MN, Gulati S, et al. Randomized
264 clinical trial of percutaneous transluminal angioplasty, supervised exercise and combined treatment
265 for intermittent claudication due to femoropopliteal arterial disease. *The British journal of surgery.*
266 2012;99(1):39-48.

- 267 44. Meneses AL, de Lima GH, Forjaz CL, Lima AH, Silva GQ, Cucato GG, et al. Impact of a
268 supervised strength training or walking training over a subsequent unsupervised therapy period on
269 walking capacity in patients with claudication. *Journal of vascular nursing : official publication of the*
270 *Society for Peripheral Vascular Nursing*. 2011;29(2):81-6.
- 271 45. Mika P, Spodaryk K, Cencora A, Unnithan VB, Mika A. Experimental model of pain-free
272 treadmill training in patients with claudication. *American journal of physical medicine &*
273 *rehabilitation / Association of Academic Physiatrists*. 2005;84(10):756-62.
- 274 46. Mika P, Spodaryk K, Cencora A, Mika A. Red blood cell deformability in patients with
275 claudication after pain-free treadmill training. *Clinical journal of sport medicine : official journal of*
276 *the Canadian Academy of Sport Medicine*. 2006;16(4):335-40.
- 277 47. Mika P, Wilk B, Mika A, Marchewka A, Nizankowski R. The effect of pain-free treadmill
278 training on fibrinogen, haematocrit, and lipid profile in patients with claudication. *European journal*
279 *of cardiovascular prevention and rehabilitation : official journal of the European Society of*
280 *Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise*
281 *Physiology*. 2011;18(5):754-60.
- 282 48. Mockford KA, Gohil RA, Mazari F, Khan JA, Vanicek N, Coughlin PA, et al. Effect of supervised
283 exercise on physical function and balance in patients with intermittent claudication. *The British*
284 *journal of surgery*. 2014;101(4):356-62.
- 285 49. Nicolai SP, Teijink JA, Prins MH, Exercise Therapy in Peripheral Arterial Disease Study G.
286 Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus
287 walking advice for intermittent claudication. *Journal of vascular surgery*. 2010;52(2):348-55.
- 288 50. Parmenter BJ, Raymond J, Dinnen P, Lusby RJ, Fiatarone Singh MA. High-intensity
289 progressive resistance training improves flat-ground walking in older adults with symptomatic
290 peripheral arterial disease. *Journal of the American Geriatrics Society*. 2013;61(11):1964-70.
- 291 51. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients
292 with peripheral arterial disease. *Journal of vascular surgery*. 1996;23(1):104-15.
- 293 52. Sakamoto S, Yokoyama N, Tamori Y, Akutsu K, Hashimoto H, Takeshita S. Patients with
294 peripheral artery disease who complete 12-week supervised exercise training program show
295 reduced cardiovascular mortality and morbidity. *Circulation journal : official journal of the Japanese*
296 *Circulation Society*. 2009;73(1):167-73.
- 297 53. Savage P, Ricci MA, Lynn M, Gardner A, Knight S, Brochu M, et al. Effects of home versus
298 supervised exercise for patients with intermittent claudication. *Journal of cardiopulmonary*
299 *rehabilitation*. 2001;21(3):152-7.
- 300 54. Schlager O, Giurgea A, Schuhfried O, Seidinger D, Hammer A, Groger M, et al. Exercise
301 training increases endothelial progenitor cells and decreases asymmetric dimethylarginine in
302 peripheral arterial disease: a randomized controlled trial. *Atherosclerosis*. 2011;217(1):240-8.
- 303 55. Slordahl SA, Wang E, Hoff J, Kemi OJ, Amundsen BH, Helgerud J. Effective training for
304 patients with intermittent claudication. *Scandinavian cardiovascular journal : SCJ*. 2005;39(4):244-9.
- 305 56. Spronk S, Bosch JL, den Hoed PT, Veen HF, Pattynama PM, Hunink MG. Intermittent
306 claudication: clinical effectiveness of endovascular revascularization versus supervised hospital-
307 based exercise training--randomized controlled trial. *Radiology*. 2009;250(2):586-95.
- 308 57. Stewart AH, Smith FC, Baird RN, Lamont PM. Local versus systemic mechanisms underlying
309 supervised exercise training for intermittent claudication. *Vascular and endovascular surgery*.
310 2008;42(4):314-20.
- 311 58. Tew GA, Nawaz S, Blagojevic M, Zwierska I, Saxton JM. Physiological predictors of maximum
312 treadmill walking performance in patients with intermittent claudication. *International journal of*
313 *sports medicine*. 2009;30(6):467-72.
- 314 59. Treat-Jacobson D, Bronas UG, Leon AS. Efficacy of arm-ergometry versus treadmill exercise
315 training to improve walking distance in patients with claudication. *Vasc Med*. 2009;14(3):203-13.

316 60. Tsai JC, Chan P, Wang CH, Jeng C, Hsieh MH, Kao PF, et al. The effects of exercise training on
317 walking function and perception of health status in elderly patients with peripheral arterial occlusive
318 disease. *Journal of internal medicine*. 2002;252(5):448-55.

319 61. van Pul KM, Kruidenier LM, Nicolai SP, de Bie RA, Nieman FH, Prins MH, et al. Effect of
320 supervised exercise therapy for intermittent claudication in patients with diabetes mellitus. *Annals*
321 *of vascular surgery*. 2012;26(7):957-63.

322 62. Versluis B, Leiner T, Nelemans PJ, Wildberger JE, Schurink GW, Backes WH. Magnetic
323 resonance imaging-based monitoring of collateral artery development in patients with intermittent
324 claudication during supervised exercise therapy. *Journal of vascular surgery*. 2013;58(5):1236-43.

325 63. Walker RD, Nawaz S, Wilkinson CH, Saxton JM, Pockley AG, Wood RF. Influence of upper-
326 and lower-limb exercise training on cardiovascular function and walking distances in patients with
327 intermittent claudication. *Journal of vascular surgery*. 2000;31(4):662-9.

328 64. Wang J, Zhou S, Bronks R, Graham J, Myers S. Supervised exercise training combined with
329 ginkgo biloba treatment for patients with peripheral arterial disease. *Clinical rehabilitation*.
330 2007;21(7):579-86.

331 65. Wang J, Zhou S, Bronks R, Graham J, Myers S. Effects of supervised treadmill walking training
332 on calf muscle capillarization in patients with intermittent claudication. *Angiology*. 2009;60(1):36-41.

333 66. Wang E, Helgerud J, Loe H, Indseth K, Kaehler N, Hoff J. Maximal strength training improves
334 walking performance in peripheral arterial disease patients. *Scandinavian journal of medicine &*
335 *science in sports*. 2010;20(5):764-70.

336 67. Zwierska I, Walker RD, Choksy SA, Male JS, Pockley AG, Saxton JM. Upper- vs lower-limb
337 aerobic exercise rehabilitation in patients with symptomatic peripheral arterial disease: a
338 randomized controlled trial. *Journal of vascular surgery*. 2005;42(6):1122-30.

339 68. Tew G, Nawaz S, Zwierska I, Saxton JM. Limb-specific and cross-transfer effects of arm-crank
340 exercise training in patients with symptomatic peripheral arterial disease. *Clin Sci (Lond)*.
341 2009;117(12):405-13.

342 69. Gardner AW, Katzel LI, Sorkin JD, Goldberg AP. Effects of long-term exercise rehabilitation on
343 claudication distances in patients with peripheral arterial disease: a randomized controlled trial.
344 *Journal of cardiopulmonary rehabilitation*. 2002;22(3):192-8.

345 70. McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, et al. Treadmill exercise and
346 resistance training in patients with peripheral arterial disease with and without intermittent
347 claudication: a randomized controlled trial. *Jama*. 2009;301(2):165-74.

348 71. Popplewell MA, Bradbury AW. Why do health systems not fund supervised exercise
349 programmes for intermittent claudication? *Eur J Vasc Endovasc Surg*. 2014;48(6):608-10.

350 72. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society
351 Consensus for the Management of Peripheral Arterial Disease (TASC II). *Journal of vascular surgery*.
352 2007;45 Suppl S:S5-67.

353 73. Parmenter BJ, Raymond J, Dinnen P, Singh MA. A systematic review of randomized
354 controlled trials: Walking versus alternative exercise prescription as treatment for intermittent
355 claudication. *Atherosclerosis*. 2011;218(1):1-12.

356 74. Al-Jundi W, Madbak K, Beard JD, Nawaz S, Tew GA. Systematic review of home-based
357 exercise programmes for individuals with intermittent claudication. *European journal of vascular and*
358 *endovascular surgery : the official journal of the European Society for Vascular Surgery*.
359 2013;46(6):690-706.

360 75. Gommans LN, Saarloos R, Scheltinga MR, Houterman S, de Bie RA, Fokkenrood HJ, et al.
361 Editor's choice--The effect of supervision on walking distance in patients with intermittent
362 claudication: a meta-analysis. *European journal of vascular and endovascular surgery : the official*
363 *journal of the European Society for Vascular Surgery*. 2014;48(2):169-84.

364 76. Cunningham MA, Swanson V, O'Carroll RE, Holdsworth RJ. Randomized clinical trial of a brief
365 psychological intervention to increase walking in patients with intermittent claudication. The British
366 journal of surgery. 2012;99(1):49-56.

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381